Val-Cit-PAB-MMAE(CAS: 644981-35-1)

Val-Cit-PAB-MMAE (CAS: 644981-35-1) falls under the scope of the REACH regulations in the European Union, requiring manufacturers and importers to register substances with the European Chemicals Agency. In the United States, it is regulated by the FDA and EPA under the Toxic Substances Control Act (TSCA). It is also classified according to the Globally Harmonized System (GHS) as a hazardous chemical, requiring appropriate safety data sheets (SDS) and labeling.

There are several alternatives to Val-Cit-PAB-MMAE (CAS: 644981-35-1) in synthesis, including the use of other monoepothilones or modifications of the existing structure. Common substitutes include other MMAE derivatives, such as monomethylauristatin E (MMAE) itself, or related epothilones that offer similar cell cycle arrest properties in cancer therapy.

Val-Cit-PAB-MMAE (CAS: 644981-35-1) is primarily used in research for its anti-cancer properties. Recent market trends indicate a growing interest in its application in combination therapies, as well as in the development of novel delivery systems to enhance its therapeutic efficacy. Research is also focusing on understanding its mechanism of action and optimizing its chemical structure for improved potency and reduced toxicity.

Waste containing Val-Cit-PAB-MMAE (CAS: 644981-35-1) should be collected in appropriate, leak-proof containers and stored in a secure, designated area. It should be treated as a hazardous material and disposed of through a professional waste disposal service that complies with local and national regulations. Environmental protection measures include neutralization of the waste to reduce toxicity and proper incineration or other safe disposal methods to prevent environmental contamination.